The healthcare sector is undergoing rapid, momentous change. The combination of ongoing technological development and far-reaching regulatory change means that no business model can survive without constant revision and rejuvenation. Hospitals, insurers, pharmaceutical companies, investors, start-ups and other organizations all need to compete in a uniquely complex and fast-evolving strategic space. To lead in healthcare, to launch something new, to create value for your stakeholders, you need a fundamental understanding of markets and organizations combined with deep insight into healthcare’s challenges.
Yale’s first-rate business curriculum and depth of knowledge in the sector provide a foundation for your aspirations. You’ll also draw on the full power of Yale University and our network of business graduates in the field, as you gain the elevated perspective to see the big picture that enables you to be a leader.
"The combination of the rigorous Yale MBA and in-depth study of healthcare leadership has been a winning formula for our graduates over the past years as evidenced by the impact they are having across the sector.”
—Howard P. Forman, Faculty Director, Healthcare, & Professor of Diagnostic Radiology, Economics, and Management
Alongside the integrated core curriculum, in your first year, you will increase your grasp of big ideas and trends in healthcare by participating in the Colloquium on Healthcare, a series of candid talks with leaders of hospitals, CEOs of medical device and drug companies, policymakers, and other people shaping the field. In addition, you will build your network and benefit from the perspectives and experiences of classmates from all facets of the industry.
In the second year, you deepen your expertise. You take a slate of advanced business and management courses, and a series of deep explorations of topics in healthcare. These courses are taught by experts from the School of Management and other parts of the university, including the School of Medicine and the School of Public Health. A capstone course structured around major challenges in healthcare will deepen your learning and link back to the essential business skills taught in the core.
Healthcare Economics: This course will provide an introduction to the economics of healthcare markets with a focus on understanding what is inefficient, what reforms and innovations might make things better and how strategic interactions among firms impact profits, health outcomes, and social welfare. Topics covered will include: measuring the value of health and medical care; the role of health insurance and competition among insurers; assessing healthcare delivery facilities such as hospitals, nursing homes and retail clinics; whether pharmaceutical prices are too high and whether we should purchase pharmaceuticals from other counties; lessons from behavioral economics about the role of imperfectly informed consumers; and the impact of the Affordable Care Act on health care in the US.
The course will focus on the most critical issues in global health in the era of Sustainable Development Goals (SDGs), particularly in low- and middle-income countries (LMICs), and cost-effective innovative solutions. The course will examine the following to set a foundation for understanding global health issues:
- Who are the key global health actors? What are their roles?
- The burden of disease, risk factors, and social determinants of health
- Demography and health – How will population aging broadly and continued population growth in many of today’s LMICs affect the global burden of disease?
- What are the key issues facing health systems in LMICs and how are countries seeking to address them?
- Comparative health systems and health system reform – How have different countries, richer and poorer, sought to address key health system issues and what can we learn from their experience?
- The health of women and children, and communicable and non-communicable diseases – We will focus on maternal and child health issues, HIV, TB, malaria, and Neglected Tropical Diseases.
- What are the constraints to the development of the diagnostics, drugs, and vaccines that are needed to meet the health needs of the poor in low- and middle-income countries?
- What are some of the innovative approaches that have been taken to addressing global public goods in health?
- Future challenges in global health
The course will also examine how one might apply the following approaches to addressing some of the most important issues noted above:
- Community-based NGO-led efforts
- Social and other forms of insurance
- Public-private partnerships
- Product development partnerships
- Innovative financing
- Social impact bonds
- Social entrepreneurship
- Corporate social responsibility
Each class session will be divided roughly into two parts. The first will cover “content” issues. The second will cover various approaches, as noted above, to addressing those issues.
The healthcare delivery system is made up of many organizations from large hospitals to small private practices. The operations of these organizations are complex as they involve many highly trained professionals with a wide range of specializations, sophisticated and expensive technology and customers (patients) with diverse needs all in an environment that is increasingly cost sensitive. At the same time quality is multidimensional and hard to measure. In this course we study the concepts and tools that can increase the efficiency and quality of healthcare delivery processes. We will explore questions of capacity planning, scheduling and process design in healthcare. We will use quantitative analysis tools such as Queuing analysis and Monte Carlo simulation. An important part of the course is a project described below.
Healthcare Policy, Finance and Economic
Survey course that looks at demand-side and supply-side factors that influence the delivery of healthcare and health in the US. The course, inherently, challenges the student to consider the appropriate role of government in the US healthcare delivery system.
Population Health & Health Equity
The concept of population health is relatively new but is quickly gaining traction within healthcare delivery systems across the United States. New value models of care linked with reimbursement policies—accountable care organizations and accountable health communities—are central to this shifting emphasis. Accountable care organizations (ACO’s) are typically regional groups of clinicians and hospitals who voluntarily work together with a goal to provide high quality, coordinated care to their shared Medicare patients. ACO members are financially incentivized as they share in any realized health care savings. Accountable health communities (AHC’s), currently being piloted at 32 organizations across the country and supported by the Centers for Medicare and Medicaid Services, ideally involve multiple stakeholders working together to improve the health and well-being of their communities, however defined, by addressing social and structural health determinants. ACO’s → AHC’s represents a possible evolution of attempts to achieve the Triple Aim: 1) reduction of health care costs, 2) improvement of patient-centered health care experiences (inclusive of quality of care), and 3) improvement in
Population health and health equity frameworks share the recognition that unmet health-related social needs, such as food and/or housing insecurity, may increase the risk of developing chronic conditions and reduce an individual’s ability to manage those conditions. Population health, in turn, has a focus on reducing the avoidable healthcare utilization and increased healthcare costs that are often the resulting reality. The focus of health equity, a long-standing framework anchored in social justice, is on the equal distribution of good health with a specific emphasis on groups that are stigmatized, marginalized, and disadvantaged as a result of historical and contemporary policies across domains that systematically affect access to opportunity. Important tensions exist between population health and health equity paradigms.
The advent of precision medicine/precision health initiatives, an evolution of the personalized medicine movement, furthers intense debate regarding the role of advanced and expensive clinical interventions in achieving the health of groups and populations. At one end of the argument-- a focus on precision medicine is societally expensive, will exacerbate health inequities, and promises unrealistic applications and outcomes. Resources may be concentrated among the relative few who have access to new technologies, accurate disease prediction (and prevention) is a distant scientific goal dependent on more than genetic predispositions, the shift in research and care delivery funding might orphan innovations targeted at disparity populations, and the focus on the individual may lead to less sophisticated understanding of structural realities that disadvantage groups. Others argue precision medicine holds great promise in achieving population health and health equity. Conceptualizing precision medicine as beyond biological and genetic markers allows for the emergence of precision population health and other frameworks that give equal stature to contextual considerations such as environmental exposures and the landscape of health-impacting policies. Even if narrowly envisioned as genetic and genomic targets, pharmacogenetics and genetic approaches to screening for some conditions hold significant promise. Further, the power of precision medicine to call into question widely held biological assumptions about “race” and other forms of social groupings is also worthy of consideration.
The emergence of powerful patient advocacy voices has paralleled the ascent of population health and precision medicine paradigms. As groups organize around shared diagnoses and advocacy agendas, their influence on how healthcare and research dollars are spent is encouraged and supported through initiatives such as the Patient-Centered Outcomes Research Institute. The All of Us cohort study, funded as part of the Precision Medicine Institute by the National Institutes of Health, also seeks to engage patient representative groups in the work of following one million American lives over time. Emerging networks, such as Patients Like Me, and established networks are able to influence the priorities of pharmaceutical companies, governmental organizations, funders, and researchers. The effects of these new patient data economies are poorly understand in the context of health equity and population health.
The course will introduce and examine the intersections between social phenomenon, health care delivery system incentives, technological advances, patient engagement, and health outcomes across groups in the United States. The tension and synergies across prevailing frameworks will be illustrated. Opportunities to innovate and advance both population health and health equity will be highlighted and identified.
Sustainable Innovation in Healthcare
Explores the practical issues of managing ongoing innovation in the healthcare industry through the lens of analyzing how executives meet the need for the continuous advancements in quality, technology and efficiency in the development, marketing and sales of pharmaceutical products, health technology and patient service delivery. The course combines case discussion, lectures, seminar-style interactions and guest executive speakers. Students are expected to actively participate in classroom discussions, and prepare for each class by completing assigned readings and discussion questions. There will be one group assignment that will require students to work in small teams and prepare a short presentation analyzing innovation at a public company or other healthcare organization.
This list represents current and planned program content. Exact course lineup and/or titles may change.
September 20, 2019
January 24, 2020
October 4, 2019
February 7, 2020
November 1, 2019
March 6, 2020
November 15, 2019
April 3, 2020